Xenon Pharmaceuticals Inc. financial data

Symbol
XENE on Nasdaq
Industry
Pharmaceutical Preparations
Location
200 3650 Gilmore Way, Burnaby, British Columbia, Canada
State of incorporation
British Columbia, Canada
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.37 K % -31.5%
Debt-to-equity 4.56 % +22.3%
Return On Equity -24.4 % -21.7%
Return On Assets -23.3 % -20.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 75.4 M shares +18.7%
Common Stock, Shares, Outstanding 75.5 M shares +19.6%
Entity Public Float 2.44 B USD +29.9%
Common Stock, Value, Issued 1.44 B USD +34.1%
Weighted Average Number of Shares Outstanding, Basic 77.6 M shares +18.1%
Weighted Average Number of Shares Outstanding, Diluted 77.6 M shares +18.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 172 M USD +36.8%
General and Administrative Expense 51.8 M USD +45.6%
Operating Income (Loss) -224 M USD -39.3%
Nonoperating Income (Expense) 35.3 M USD +148%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -189 M USD -28.7%
Income Tax Expense (Benefit) -170 K USD -121%
Net Income (Loss) Attributable to Parent -189 M USD -27.9%
Earnings Per Share, Basic -2.72 USD/shares -16.2%
Earnings Per Share, Diluted -2.72 USD/shares -16.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 58.9 M USD -15.3%
Marketable Securities, Current 641 M USD +40%
Accounts Receivable, after Allowance for Credit Loss, Current 833 K USD -62.5%
Assets, Current 707 M USD +32.6%
Deferred Income Tax Assets, Net 400 K USD +81%
Property, Plant and Equipment, Net 9.39 M USD +17.8%
Operating Lease, Right-of-Use Asset 8.88 M USD -12%
Assets 919 M USD +27.7%
Employee-related Liabilities, Current 3.82 M USD +43.1%
Liabilities, Current 22.2 M USD -1.19%
Operating Lease, Liability, Noncurrent 9.1 M USD -12.8%
Liabilities 31.3 M USD -4.86%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.77 M USD +2.8%
Retained Earnings (Accumulated Deficit) -713 M USD -36%
Stockholders' Equity Attributable to Parent 888 M USD +29.2%
Liabilities and Equity 919 M USD +27.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -43.2 M USD -25.5%
Net Cash Provided by (Used in) Financing Activities 354 M USD +27%
Net Cash Provided by (Used in) Investing Activities -46.2 M USD -199%
Common Stock, Shares, Issued 75.5 M shares +19.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -89.7 M USD -831%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 214 M USD +30.2%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.27 pure 0%
Operating Lease, Liability 10.4 M USD -10.3%
Payments to Acquire Property, Plant, and Equipment 188 K USD -91.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -189 M USD -27.2%
Lessee, Operating Lease, Liability, to be Paid 11.9 M USD -12.1%
Operating Lease, Liability, Current 1.32 M USD +10.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.82 M USD +3.83%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.75 M USD +3.99%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure 0%
Deferred Income Tax Expense (Benefit) 403 K USD +39.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.5 M USD -22.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.8 M USD -0.77%
Deferred Tax Assets, Operating Loss Carryforwards 120 M USD +48.7%
Preferred Stock, Shares Issued 0 shares -100%
Unrecognized Tax Benefits 10.9 M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.1 M USD -38.9%
Operating Lease, Payments 411 K USD +1.23%
Preferred Stock, Shares Outstanding 0 shares -100%
Deferred Tax Assets, Net of Valuation Allowance 802 K USD +57.6%
Share-based Payment Arrangement, Expense 32.4 M USD +58.9%